{"nctId":"NCT01194414","briefTitle":"A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis","startDateStruct":{"date":"2010-09"},"conditions":["Rheumatoid Arthritis"],"count":1262,"armGroups":[{"label":"Tocilizumab SC","type":"EXPERIMENTAL","interventionNames":["Drug: tocilizumab SC","Drug: placebo to tocilizumab IV","Drug: Disease-modifying antirheumatic drugs (DMARDs)"]},{"label":"Tocilizumab IV","type":"EXPERIMENTAL","interventionNames":["Drug: tocilizumab IV","Drug: placebo to tocilizumab SC","Drug: Disease-modifying antirheumatic drugs (DMARDs)"]},{"label":"Tocilizumab SC Then Tocilizumab IV","type":"EXPERIMENTAL","interventionNames":["Drug: tocilizumab SC","Drug: tocilizumab IV","Drug: placebo to tocilizumab IV","Drug: Disease-modifying antirheumatic drugs (DMARDs)"]},{"label":"Tocilizumab IV Then Tocilizumab SC","type":"EXPERIMENTAL","interventionNames":["Drug: tocilizumab SC","Drug: tocilizumab IV","Drug: placebo to tocilizumab SC","Drug: Disease-modifying antirheumatic drugs (DMARDs)"]}],"interventions":[{"name":"tocilizumab SC","otherNames":["RoActemra/Actemra"]},{"name":"tocilizumab IV","otherNames":["RoActemra/Actemra"]},{"name":"placebo to tocilizumab SC","otherNames":[]},{"name":"placebo to tocilizumab IV","otherNames":[]},{"name":"Disease-modifying antirheumatic drugs (DMARDs)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult participants, ≥ 18 years of age\n* Rheumatoid arthritis of ≥ 6 months duration, according to American College of Rheumatology (ACR) criteria\n* Swollen joint count (SJC) ≥ 4 (66 joint count), tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline\n* Inadequate response to current DMARD therapy\n* Permitted DMARDs must be at stable dose for ≥ 8 weeks prior to baseline\n* Oral corticosteroids (≤ 10 mg/day prednisone or equivalent) and NSAIDs (up to maximum recommended dose) must be at stable dose for ≥ 4 weeks prior to baseline\n\nExclusion Criteria:\n\n* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization\n* Rheumatic autoimmune disease other than RA\n* Functional class IV (ACR classification)\n* Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis (JRA) and/or RA before the age of 16\n* Prior history of or current inflammatory joint disease other than RA\n* Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline\n* Previous treatment with tocilizumab\n* Active current or history of recurrent infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24","description":"ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the five additional ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) where left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either C-reactive protein \\[CRP\\] or Erythrocyte Sedimentation Rate \\[ESR\\]).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.4","spread":null},{"groupId":"OG001","value":"73.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory Assessments","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.6","spread":null},{"groupId":"OG001","value":"87.8","spread":null},{"groupId":"OG002","value":"81.3","spread":null},{"groupId":"OG003","value":"86.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":null},{"groupId":"OG001","value":"12.7","spread":null},{"groupId":"OG002","value":"12.5","spread":null},{"groupId":"OG003","value":"11.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"28.2","spread":null},{"groupId":"OG002","value":"25.0","spread":null},{"groupId":"OG003","value":"19.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR50) Response at Week 24","description":"ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the five additional ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) where left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either C-reactive protein or Erythrocyte Sedimentation Rate).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.0","spread":null},{"groupId":"OG001","value":"48.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR70) Response at Week 24","description":"ACR70 response is defined as a ≥ 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the five additional ACR core set variables: Patient's Assessment of Pain over the previous 24 hours using a Visual Analog Scale (VAS) where left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either C-reactive protein or Erythrocyte Sedimentation Rate).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"27.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Activity Score 28 (DAS28) Remission at Week 24","description":"The DAS28 (ESR) score is a measure of the subject's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity VAS where left side of the line 0=no disease activity to right side of the line 100=extreme disease activity and ESR. DAS28-(ESR) total scores range from 0 - 10. Remission is defined as achieving a DAS28-ESR score of less than 2.6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":null},{"groupId":"OG001","value":"36.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Decrease of ≥ 0.3 in the Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline to Week 24","description":"The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a participant completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do).HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A decrease indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":null},{"groupId":"OG001","value":"67.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Withdrew Because of Lack of Therapeutic Response at Week 24","description":"The percentage of participants who withdrew from the study because they were not responding to treatment with the study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With American College of Rheumatology Criteria (ACR20, ACR50, ACR70) at Week 97","description":"ACR20, ACR50 and ACR70: ≥20%, ≥50% and ≥70% reduction from baseline for both TJC68 and SJC66, as well as for 3 of 5 additional ACR variables: Patient's Assessment of Pain in last 24 hours using a Visual Analog Scale (VAS) (0=no pain and 100=unbearable pain); Patient's and Physician's Global Assessment of Disease Activity in last 24 hours using a VAS (0=no disease activity and100=maximum disease activity); Health Assessment Questionnaire: 20 questions in 8 areas (dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities) answered on a scale of 0=without difficulty to 3=unable to do; and acute-phase reactant (either CRP or ESR). CRP was used for calculation of ACR. If missing, ESR was used. LOCF was used for missing joint counts, no imputation for other ACR components.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":null},{"groupId":"OG001","value":"83.3","spread":null},{"groupId":"OG002","value":"82.5","spread":null},{"groupId":"OG003","value":"88.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.4","spread":null},{"groupId":"OG001","value":"62.5","spread":null},{"groupId":"OG002","value":"57.5","spread":null},{"groupId":"OG003","value":"67.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":null},{"groupId":"OG001","value":"42.0","spread":null},{"groupId":"OG002","value":"37.5","spread":null},{"groupId":"OG003","value":"47.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Activity Score 28 (DAS28) Remission at Week 97","description":"The DAS28 (ESR) score is a measure of the subject's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity VAS where left side of the line 0=no disease activity to right side of the line 100=extreme disease activity and ESR. DAS28-(ESR) total scores range from 0 - 10. Remission is defined as achieving a DAS28-ESR score of less than 2.6. LOCF used for tender and swollen joint counts, no imputation used for ESR and Patient's Global Assessment of Disease Activity VAS.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"46.4","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"55.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving a Decrease of ≥0.3 in the Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline to Week 97","description":"The Stanford Health Assessment Questionnaire disability index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each domain has at least two component questions. There are four possible responses for each component ranging from 0(without any difficulty) to 4 (unable to do).HAQ-DI=sum of worst scores in each domain divided by the number of domains answered. A decrease indicates improvement. No imputation of missing scores was made other than for missing baseline scores, for which last score prior to baseline will be carried forward. For participants who prematurely withdrew, data collected at withdrawal visit was used and data thereafter is missing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.4","spread":null},{"groupId":"OG001","value":"69.1","spread":null},{"groupId":"OG002","value":"56.4","spread":null},{"groupId":"OG003","value":"71.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Withdrew Because of Lack of Therapeutic Response at Week 97","description":"The percentage of participants who withdrew from the study because they were not responding to treatment with the study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"3.0","spread":null},{"groupId":"OG002","value":"4.2","spread":null},{"groupId":"OG003","value":"1.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Serum Concentration Curve of Tocilizumab After First SC Injection or IV Infusion","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1444","spread":"839"},{"groupId":"OG001","value":"30988","spread":"9114"}]}]}]},{"type":"SECONDARY","title":"Area Under the Serum Concentration Curve of Tocilizumab at Steady State for SC and IV Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7542","spread":"3989"},{"groupId":"OG001","value":"41304","spread":"15104"}]}]}]},{"type":"SECONDARY","title":"Minimum Serum Concentration (Cmin) of Tocilizumab","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.48","spread":"4.91"},{"groupId":"OG001","value":"6.65","spread":"6.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":"16.2"},{"groupId":"OG001","value":"16.0","spread":"10.3"}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration (Cmax) of Tocilizumab","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"8.74"},{"groupId":"OG001","value":"180","spread":"40.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":"27.3"},{"groupId":"OG001","value":"233","spread":"117"}]}]}]},{"type":"SECONDARY","title":"Time to Maximum Serum Concentration (Tmax) of Tocilizumab","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Interleukin-6 (IL-6) Concentration at Week 25","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.04","spread":"55.456"},{"groupId":"OG001","value":"52.48","spread":"240.964"},{"groupId":"OG002","value":"62.18","spread":"125.081"},{"groupId":"OG003","value":"50.07","spread":"161.045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.42","spread":"110.842"},{"groupId":"OG001","value":"52.61","spread":"507.157"},{"groupId":"OG002","value":"37.54","spread":"93.464"},{"groupId":"OG003","value":"44.12","spread":"136.955"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Soluble Interleukin-6 Receptor (sIL-6R) Concentration at Week 97","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.53","spread":"35.470"},{"groupId":"OG001","value":"45.72","spread":"40.219"},{"groupId":"OG002","value":"44.71","spread":"13.068"},{"groupId":"OG003","value":"43.28","spread":"16.197"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"601.52","spread":"222.141"},{"groupId":"OG001","value":"575.75","spread":"244.398"},{"groupId":"OG002","value":"569.60","spread":"213.588"},{"groupId":"OG003","value":"586.50","spread":"226.915"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Developed Antibodies To Tocilizumab at Week 97","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":88,"n":631},"commonTop":["Alanine aminotransferase increased","Upper respiratory tract infection","Aspartate aminotransferase increased","Nasopharyngitis","Urinary tract infection"]}}}